Enveric Biosciences Inc
Research Enveric Biosciences Inc (ENVB) on Bullrun: market cap USD 2.76M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerENVB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.76M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 1.63M
- Free cash flow-USD 2.26M
Valuation Snapshot
latest market cap is USD 2.76M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | USD 12.10M | -USD 8.14M | n/a | -36.24 | USD 4.68M | n/a | USD 4.18M |
| FY2024 | USD 0 | USD 9.60M | -USD 7.73M | n/a | -228.48 | USD 2.24M | n/a | USD 1.59M |
| FY2023 | n/a | USD 17.50M | -USD 14.10M | n/a | -121.29 | USD 2.29M | USD 0 | USD 1.96M |
| FY2022 | n/a | -USD 18.47M | -USD 17.73M | n/a | -13 | USD 17.72M | USD 63.82K | USD 14.67M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.76M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.71M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 54.61M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 45.28M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 64.58M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 451.98M | n/a | n/a | n/a |
About Enveric Biosciences Inc
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Enveric Biosciences Inc's market cap?
Enveric Biosciences Inc's market capitalization is USD 2.76M.
What does Enveric Biosciences Inc do?
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc.